Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. Cooperberg MR, et al. Among authors: zhu k. JAMA Oncol. 2020 Oct 1;6(10):e203187. doi: 10.1001/jamaoncol.2020.3187. Epub 2020 Oct 8. JAMA Oncol. 2020. PMID: 32852532 Free PMC article.
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: zhu k. J Urol. 2020 Apr;203(4):727-733. doi: 10.1097/JU.0000000000000621. Epub 2019 Oct 25. J Urol. 2020. PMID: 31651227 Free PMC article.
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: zhu k. J Urol. 2020 Apr;203(4):733. doi: 10.1097/JU.0000000000000621.02. Epub 2020 Jan 17. J Urol. 2020. PMID: 31951502 No abstract available.
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: zhu k. J Urol. 2021 Feb;205(2):339-340. doi: 10.1097/JU.0000000000001444. Epub 2020 Nov 6. J Urol. 2021. PMID: 33155864 No abstract available.
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Kirk PS, et al. Among authors: zhu k. Cancer. 2022 Jan 15;128(2):269-274. doi: 10.1002/cncr.33911. Epub 2021 Sep 13. Cancer. 2022. PMID: 34516660 Free PMC article.
Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
Waisman Malaret AJ, Chang P, Zhu K, Zheng Y, Newcomb LF, Liu M, McKenney JK, Brooks JD, Carroll P, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Lin DW, Wagner AA. Waisman Malaret AJ, et al. Among authors: zhu k. J Urol. 2022 Apr;207(4):805-813. doi: 10.1097/JU.0000000000002354. Epub 2021 Dec 2. J Urol. 2022. PMID: 34854745 Free PMC article.
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
Brady L, Newcomb LF, Zhu K, Zheng Y, Boyer H, Sarkar N, McKenney JK, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, Morgan TM, Thompson IM, Wagner AA, Pritchard CC, Lin DW, Nelson PS. Brady L, et al. Among authors: zhu k. Cancer Med. 2022 Nov;11(22):4332-4340. doi: 10.1002/cam4.4778. Epub 2022 Apr 25. Cancer Med. 2022. PMID: 35467778 Free PMC article.
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
Filson CP, Zhu K, Huang Y, Zheng Y, Newcomb LF, Williams S, Brooks JD, Carroll PR, Dash A, Ellis WJ, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Wagner AA, Sokoll LJ, Sanda MG, Chan DW, Lin DW. Filson CP, et al. Among authors: zhu k. J Urol. 2022 Nov;208(5):1037-1045. doi: 10.1097/JU.0000000000002852. Epub 2022 Jul 5. J Urol. 2022. PMID: 35830553 Free PMC article.
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
Schenk JM, Liu M, Neuhouser ML, Newcomb LF, Zheng Y, Zhu K, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: zhu k. Nutr Cancer. 2023;75(2):618-626. doi: 10.1080/01635581.2022.2143537. Epub 2022 Nov 7. Nutr Cancer. 2023. PMID: 36343223 Free PMC article.
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort.
Waisman Malaret AJ, Chang P, Newcomb L, Faino A, Zheng Y, Zhu K, McKenney JK, Brooks JD, Dash A, Ellis WJ, Filson CP, Gleave M, Liss M, Martin FM, Morgan T, Carroll P, Nelson P, Lin DW, Wagner AA. Waisman Malaret AJ, et al. Among authors: zhu k. Urol Pract. 2021 Sep;8(5):576-582. doi: 10.1097/UPJ.0000000000000245. Epub 2021 Jun 25. Urol Pract. 2021. PMID: 37145399
5,544 results